Un tânăr a fost tratat în premieră, în Germania, cu tehnologia de editare genetică CRISPR / Fără tratament avea nevoie de transfuzii de sânge la fiecare 3 săptămâni

A 19-year-old patient in Germany has been successfully treated with a CRISPR-based drug for beta-thalassemia, marking a medical milestone. The treatment, Casgevy, has allowed him to no longer require blood transfusions. His immune system has regenerated, and he is feeling well. Casgevy is set to be approved in the EU in 2024 for certain patients. Beta-thalassemia, a genetic blood disorder, affects many children worldwide, necessitating frequent blood transfusions that can have serious long-term side effects. The treatment, administered over 12 months, was first given to Mohammad in May 2026, as he was too old for a stem cell transplant. The developers of this CRISPR technology received the Nobel Prize in 2020, although some experts express concerns about its complexity and limited availability.